RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Chugai Pharmaceutical Co P/E 2024

Chugai Pharmaceutical Co P/E

23.4

Chugai Pharmaceutical Co Dividend yield

1.63 %

Ticker

4519.T

ISIN

JP3519400000

WKN

857216

As of Apr 20, 2024, Chugai Pharmaceutical Co's P/E ratio was 23.4, a 21.43% change from the 19.27 P/E ratio recorded in the previous year.

The Chugai Pharmaceutical Co P/E history

Chugai Pharmaceutical Co Aktienanalyse

What does Chugai Pharmaceutical Co do?

Chugai Pharmaceutical Co Ltd is a Japanese pharmaceutical company founded in 1925. It is headquartered in Tokyo and employs over 7,500 employees worldwide. Chugai is one of the largest pharmaceutical companies in Japan and has become a global company with a strong research and development department in recent decades. The business model of Chugai is based on the development and production of drugs for various medical conditions, with a focus on cancer therapy. However, Chugai also has drugs for other medical conditions in its portfolio, such as rheumatism, asthma, and diabetes. The company specializes in research and development of biotechnological therapeutics and has focused on the study of biological agents. Chugai's goal is to improve people's lives and enhance patient care. Chugai is divided into several business units, each focusing on different areas of therapy. One of these areas is oncology. Chugai has a strong range of oncology products, for which it is a market leader in Japan. These include Avastin, an anti-angiogenesis drug for the treatment of colorectal, breast, lung, and kidney cancer, as well as Herceptin for the treatment of breast and gastric cancer, and Tarceva for treating bronchial carcinomas. Another important business area of Chugai is rheumatology. Here, Chugai offers various products such as Actemra, a monoclonal antibody against the interleukin-6 receptor used in rheumatoid arthritis, as well as Rituxan, an antibody against the CD20 antigen used in the treatment of lymphomas. In addition to drug development and manufacturing, Chugai also conducts research and development in the field of diagnostics. This is an important complement to the company's therapeutic portfolio. Chugai develops diagnostics to improve disease diagnosis. Another important area of Chugai is the outsourcing of research and development services. Chugai collaborates with many international pharmaceutical companies, offering its expertise and infrastructure in the development of new drugs. Chugai Pharmaceuticals is a significant player in global healthcare and aims to establish itself as a leading company in biological and cellular preparation research. The company invests significant resources in the exploration of new technologies to ensure sustainable therapy options. Chugai Pharmaceuticals has built a strong presence in the global market in recent years and will continue to play an important role in the future. Chugai Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Chugai Pharmaceutical Co's P/E Ratio

The Price to Earnings (P/E) Ratio of Chugai Pharmaceutical Co is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Chugai Pharmaceutical Co's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Chugai Pharmaceutical Co is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Chugai Pharmaceutical Co’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Chugai Pharmaceutical Co Stock

What is the price-to-earnings ratio of Chugai Pharmaceutical Co?

The price-earnings ratio of Chugai Pharmaceutical Co is currently 23.4.

How has the price-earnings ratio of Chugai Pharmaceutical Co changed compared to last year?

The price-to-earnings ratio of Chugai Pharmaceutical Co has increased by 21.43% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Chugai Pharmaceutical Co high compared to other companies?

Yes, the price-to-earnings ratio of Chugai Pharmaceutical Co is high compared to other companies.

How does an increase in the price-earnings ratio of Chugai Pharmaceutical Co affect the company?

An increase in the price-earnings ratio of Chugai Pharmaceutical Co would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Chugai Pharmaceutical Co affect the company?

A decrease in the price-earnings ratio of Chugai Pharmaceutical Co would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Chugai Pharmaceutical Co?

Some factors that influence the price-earnings ratio of Chugai Pharmaceutical Co are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Chugai Pharmaceutical Co pay?

Over the past 12 months, Chugai Pharmaceutical Co paid a dividend of 80 JPY . This corresponds to a dividend yield of about 1.63 %. For the coming 12 months, Chugai Pharmaceutical Co is expected to pay a dividend of 93.2 JPY.

What is the dividend yield of Chugai Pharmaceutical Co?

The current dividend yield of Chugai Pharmaceutical Co is 1.63 %.

When does Chugai Pharmaceutical Co pay dividends?

Chugai Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of July, January, July, January.

How secure is the dividend of Chugai Pharmaceutical Co?

Chugai Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Chugai Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 93.2 JPY are expected. This corresponds to a dividend yield of 1.89 %.

In which sector is Chugai Pharmaceutical Co located?

Chugai Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Chugai Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Chugai Pharmaceutical Co from 3/1/2025 amounting to 41 JPY, you needed to have the stock in your portfolio before the ex-date on 12/27/2024.

When did Chugai Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 3/1/2025.

What was the dividend of Chugai Pharmaceutical Co in the year 2023?

In the year 2023, Chugai Pharmaceutical Co distributed 78 JPY as dividends.

In which currency does Chugai Pharmaceutical Co pay out the dividend?

The dividends of Chugai Pharmaceutical Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Chugai Pharmaceutical Co

Our stock analysis for Chugai Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Chugai Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.